No Data
Express News | Jiuqiang Bio: Obtains Three Medical Device Registration Certificates
Jiuqiang Biotech (300406): Significant increase in pathology segment; accelerated expansion of Pathology AI and overseas operations
The company released its 2025 annual report and the first-quarter report for 2026. In 2025, the company achieved operating revenue of 1.356 billion yuan, representing a year-on-year decrease of 18.29%; net profit attributable to shareholders amounted to 190 million yuan, marking a year-on-year decline of 64.35%.
JIUQIANG Biological (300406) 2025 Annual Report and 2026 Q1 Commentary: Impairment Provisions Set Bottom for 2025 Performance; Operational Turning Point Emerged in Q1 2026
Event: The company released its annual report for 2025 and the first-quarter report for 2026. In 2025, the company achieved operating revenue of 1.356 billion yuan, representing a year-on-year decrease of 18.29%; net profit attributable to shareholders reached 190 million yuan.
JiQiang Bio: First Quarter Report for 2026
JiQiang Bio: 2025 Annual Report
JiQiang Bio: Summary of the 2025 Annual Report